tbuckley/cabot-search huggingface dataset:
Vulnerability Variables Among Octogenarians Myeloma Patients: A Single-Center Analysis in 110 Patients
Authors: Maria Gavriatopoulou, Despina Fotiou, Maria Roussou, Magdalini Migkou, Ioannis Ntanasis-Stathopoulos, Nikolaos Kanellias, Dimitrios C. Ziogas, Ioannis Panagiotidis, Dimitra Gika, Evangelos Eleutherakis-Papaiakovou, Evangelos Terpos, Eftathios Kastritis, Meletios A. Dimopoulos
Journal: Blood (2017)
Publisher Correction: Zeb2 drives invasive and microbiota-dependent colon carcinoma
Authors: Karolina Slowicka, Ioanna Petta, Gillian Blancke, Esther Hoste, Emilie Dumas, Mozes Sze, Hanna Vikkula, Enrico Radaelli, Jody J. Haigh, Sven Jonckheere, Joachim Taminau, Niels Vandamme, Andy Wullaert, Eugene Tulchinsky, David Nittner, Pieter Van Vlierberghe, Gert De Hertogh, Pamela Baldin, Emre Etlioglu, Pratyaksha Wirapati, Louis Boon, Bart N. Lambrecht, Chris Callewaert, Sabine Tejpar, Steven Goossens, Geert Berx, Lars Vereecke, Geert van Loo
Journal: Nature Cancer (2020)
International external quality assessment for SARS-CoV-2 molecular detection and survey on clinical laboratory preparedness during the COVID-19 pandemic, April/May 2020
Authors: Veerle Matheeussen, Victor M Corman, Oliver Donoso Mantke, Elaine McCulloch, Christine Lammens, Herman Goossens, Daniela Niemeyer, Paul S Wallace, Paul Klapper, Hubert GM Niesters, Christian Drosten, Margareta Ieven
Journal: Eurosurveillance (2020)

Laboratory preparedness with quality-assured diagnostic assays is essential for controlling the current coronavirus disease (COVID-19) outbreak. We conducted an external quality assessment study with inactivated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) samples to support clinical laboratories with a proficiency testing option for molecular assays. To analyse SARS-CoV-2 testing performance, we used an online questionnaire developed for the European Union project RECOVER to assess molecular testing capacities in clinical diagnostic laboratories.
Increases in Health-Related Workplace Absenteeism Among Workers in Essential Critical Infrastructure Occupations During the COVID-19 Pandemic — United States, March–April 2020
Authors: Matthew R. Groenewold, Sherry L. Burrer, Faruque Ahmed, Amra Uzicanin, Hannah Free, Sara E. Luckhaupt
Journal: MMWR Morbidity and Mortality Weekly Report (2020)

During a pandemic, syndromic methods for monitoring illness outside of health care settings, such as tracking absenteeism trends in schools and workplaces, can be useful adjuncts to conventional disease reporting (1,2).Each month, CDC's National Institute for Occupational Safety and Health (NIOSH) monitors the prevalence of health-related workplace absenteeism among currently employed full-time workers in the United States, overall and by demographic and occupational subgroups, using data from the Current Population Survey (CPS).*This report describes trends in absenteeism during October 2019-April 2020, including March and April 2020, the period of rapidly accelerating transmission of SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19).Overall, the prevalence of health-related workplace absenteeism in March and April 2020 were similar to their 5-year baselines.However, compared with occupation-specific baselines, absenteeism among workers in several occupational groups that define or contain essential critical infrastructure workforce † categories was significantly higher than expected in April.Significant increases in absenteeism were observed in personal care and service § (includes child care workers and personal care aides); healthcare support ¶ ; and production** * https://www.cdc.gov/niosh/topics/absences/default.html.† https://www.cisa.gov/sites/default/files/publications/Version_3.0_CISA_Guidance_on_Essential_Critical_Infrastructure_Workers_1.pdf.§ Includes 2010 Census occupation codes 4300-4650.Examples of personal care and service occupations include childcare workers; personal and home care aides; barbers; hairstylists and cosmetologists; recreation and fitness workers; morticians; embalmers; and porters and bellhops.¶ Includes 2010 Census occupation codes 3600-3655.Examples of healthcare support occupations include nursing, psychiatric, and home health aides; various therapy aides and assistants; medical and dental assistants; and phlebotomists.** Includes 2010 Census occupation codes 7700-8750.Examples of production occupations include assemblers and fabricators; food processing workers; metal and plastic workers; printing workers; textile, apparel, and furnishing workers; woodworkers; and plant and system operators.(includes meat, poultry, and fish processing workers).Although health-related workplace absenteeism remained relatively unchanged or decreased in other groups, the increase in absenteeism among workers in occupational groups less able INSIDE
P-156 A phase Ib/II study of cetuximab and pembrolizumab in metastatic colorectal cancer
Authors: C. Fountzilas, S. Mukherjee, J. Saltzman, D. Bajor, J. Muhitch, S. Abrams, O. Maguire, H. Minderman, K. Wang, A. Hutson, K. Hicks, J. Ventola, P. Kalinski, R. Iyer, P. Boland
Journal: Annals of Oncology (2020)
Inhibition of her1 and her2 in hepatoma cells
Authors: Michael Grusch, Annemarie Losert, Natascha Erlach, Barbara Peter-Vörösmarty, Rolf Schulte-Hermann
Journal: Cancer Research (2005)

5061  The four members of the EGF-receptor family (her1-4) play important roles in development and carcinogenesis. Their overexpression in different types of cancer makes them usefull targets for therapeutic interventions. We investigated the expression of her1-4 and the effect of blocking her1 and 2 in human hepatoma cell lines. HepG2 and Hep3B cells expressed mRNA and protein of three of the four receptors. Her4 was absent from HepG2 and her3 from Hep3B cells. Both cell lines also expressed several EGF-family ligands indicating the potential for autocrine growth stimulation. Increased mRNA levels of her1-3 were also found in human hepatocellular carcinoma (HCC) specimen compared to non-tumorous liver. Treatment with Gefitinib (Iressa) or with AG1478, both specific inhibitors of her1 kinase, resulted in decreased cell numbers and increased apoptosis rates in both cell lines in a dose dependent fashion. A decrease in phosphorylation of her1 and the downstream signaling molecules ERK and Akt after EGF stimulation was observed in western blot analyses with antibodies directed against specific phosphorylation sites. Complete inhibition of her1 phosphorylation, however, was seen at concentrations about one order of magnitude lower than those needed for apoptosis induction. To check these results on a genetic basis we designed dominant negative her1 and her2 constructs, where the tyrosine kinase domain was replaced by green fluorescence protein (GFP). After transfection of Hep3B and HepG2 cells with either of these constructs and subsequent selection of stable clones a negative selection pressure against expression of GFP-tagged dominant negative her1 and 2 compared to GFP alone was observed. We next subcloned the dominant negative receptor constructs into adenoviral vectors. After infection of Hep3B cells with the resulting adenoviruses DNher1 and DNher2 (dominant negative her1 and 2, respectively) we noticed an efficient inhibition of her1 phosphorylation. In contrast to treatment with Iressa or AG1478, however, the phosphorylation status of the downstream molecules ERK and Akt did not change compared to mock infected cells. Growth and apoptosis rates of hepatoma cells were not influenced by infection with DNher1 and DNher2. DNher1 infection did, in contrast, increase apoptosis rates and block mitosis of EGF stimulated primary rat hepatocytes. We conclude that despite the presence of her1 and her2 and several EGF-family ligands in hepatoma cells, blocking her1/2 signaling appears to have only marginal effects on cell growth and survival. This may be due to the activation of additional signaling pathways in these cells. These results may also indicate that Iressa as well as AG1478 do not exclusively inhibit EGFR signaling, but may have additional yet unknown activities.
Sonic Hedgehog Is Required for Progenitor Cell Maintenance in Telencephalic Stem Cell Niches
Authors: Robert Machold, Shigemi Hayashi, Michael Rutlin, Mandar D Muzumdar, Susana Nery, Joshua G Corbin, Amel Gritli-Linde, Tammy Dellovade, Jeffery A Porter, Lee L Rubin, Henryk Dudek, Andrew P McMahon, Gord Fishell
Journal: Neuron (2003)
SO-23 Prognostic impact of microsatellite instability/mismatch repair deficiency on patients with stage III colon cancer and stage IV colorectal cancers: Analysis of 42,984 patients in the National Cancer Database (NCDB)
Authors: M. Salem, A. Puccini, S. Trufan, R. Goldberg, W. Worrilow, H. Lenz, P. Philip, A. Grothey, T. André
Journal: Annals of Oncology (2020)
The glycocalyx core protein Glypican 1 protects vessel wall endothelial cells from stiffness-mediated dysfunction and disease
Authors: Marwa Mahmoud, Mariya Mayer, Limary M Cancel, Anne Marie Bartosch, Rick Mathews, John M Tarbell
Journal: Cardiovascular Research (2020)

Abstract Aims Arterial stiffness is an underlying risk factor and a hallmark of cardiovascular diseases. The endothelial cell (EC) glycocalyx is a glycan rich surface layer that plays a key role in protecting against EC dysfunction and vascular disease. However, the mechanisms by which arterial stiffness promotes EC dysfunction and vascular disease are not fully understood, and whether the mechanism involves the protective endothelial glycocalyx is yet to be determined. We hypothesized that endothelial glycocalyx protects the endothelial cells lining the vascular wall from dysfunction and disease in response to arterial stiffness. Methods and results Cells cultured on polyacrylamide (PA) gels of substrate stiffness 10 kPa (mimicking the subendothelial stiffness of aged, unhealthy arteries) showed a significant inhibition of glycocalyx expression compared to cells cultured on softer PA gels (2.5 kPa, mimicking the subendothelial stiffness of young, healthy arteries). Specifically, gene and protein analyses revealed that a glycocalyx core protein Glypican 1 was inhibited in cells cultured on stiff PA gels. These cells had enhanced endothelial cell dysfunction as determined by enhanced cell inflammation (enhanced inflammatory gene expression, monocyte adhesion, and inhibited nitric oxide expression), proliferation, and EndMT. Removal of Glypican 1 using gene-specific silencing with siRNA or gene overexpression using a plasmid revealed that Glypican 1 is required to protect against stiffness-mediated endothelial cell dysfunction. Consistent with this, using a model of age-mediated stiffness, older mice exhibited a reduced expression of Glypican 1 and enhanced endothelial cell dysfunction compared to young mice. Glypican 1 gene deletion in knockout mice (GPC1−/−) exacerbated endothelial dysfunction in young mice, which normally had high endothelial expression, but not in old mice that normally expressed low levels. Endothelial cell dysfunction was exacerbated in young, but not aged, Glypican 1 knockout mice (GPC1−/−). Conclusion Arterial stiffness promotes EC dysfunction and vascular disease at least partly through the suppression of the glycocalyx protein Glypican 1. Glypican 1 contributes to the protection against endothelial cell dysfunction and vascular disease in endothelial cells.
Dissociable effects of dopamine and serotonin on reversal learning [Correction]
Authors: H.E.M. den Ouden, N.D. Daw, G.S.E. Fernandez, J.A. Elshout, M.J.P. Rijpkema, M. Hoogman, B. Franke, R. Cools
Journal: Neuron (2013)
Abstract 209: Does ECPR for the Younger Patients Who Has Long Downtime Improve Neurological Outcome?
Authors: Shinichi Ijuin, Akihiko Inoue, Nobuaki Igarashi, Shigenari Matsuyama, Tetsunori Kawase, Satoshi Ishihara, Shinichi Nakayama
Journal: Circulation (2019)

Introduction: It have reported previously that extracorporeal cardiopulmonary resuscitation (ECPR) for out of hospital cardiac arrest should induct within 45 minutes from collapse. However, We often encounter patients with favorable neurological outcome who had longer time interval from collapse to induction of V-A ECMO (Downtime: DT). We analyzed that relation about neurological outcome and DT for patients undergone ECPR. Methods: In this single center retrospective study, from January 2010 to April 2019, we identified 147 patients who underwent ECPR. Of these, 87 patients (59%) had shorter DT (≦45min:Group S), and 60 patients (41%) had longer DT (≧46min:Group L). We compared neurological outcome between two groups. Glasgow-Pittsburgh Cerebral Performance Category (CPC) 1-2 was defined as favorable neurological outcome, CPC3-5 was defined as unfavorable outcome at 3 months. Results were expressed as Median (IQR). Results: Patient characteristics were not different between the two groups. DT were 37 min (32-42: Group S) and 57 min (50-64: Group L). 51 % of the patients in Group S (46 patients) were alive at 3 month, as compared with 35% in Group L (21 patients) (p: 0.05). At the 3 month follow up, Group S had a higher rate of favorable neurological outcome than Group L (39% (34 patients) vs 28% (17 patients) (p:0.18 ). In younger patients (≦65y.o), the rate of favorable neurological outcome were roughly equal in each groups (Group S: 41% (20/48 patients) vs 37% (11/30 patients) ) (p:0.51). Conclusions: Because it is possible younger patients with cardiac arrest had a favorable neurological outcome, even if they had longer DT, it should consider the expanded adaptation of ECPR.
Treatment after ACL injury: Panther Symposium ACL Treatment Consensus Group
Authors: Theresa Anita Diermeier, Ben B Rothrauff, Lars Engebretsen, Andrew Lynch, Eleonor Svantesson, Eric Andrew Hamrin Senorski, Sean J Meredith, Thomas Rauer, Olufemi R Ayeni, Mark Paterno, John W Xerogeanes, Freddie H Fu, Jon Karlsson, Volker Musahl
Journal: British Journal of Sports Medicine (2020)

Treatment strategies for ACL injuries continue to evolve. Evidence supporting best practice guidelines to manage ACL injury is largely based on studies with low-level evidence. An international consensus group of experts was convened determine consensus regarding best available evidence on operative versus non-operative treatment for ACL injury. The purpose of this study is to report the consensus statements on operative versus non-operative treatment of ACL injuries developed at the ACL Consensus Meeting Panther Symposium 2019. Sixty-six international experts on the management of ACL injuries, representing 18 countries, convened and participated in a process based on the Delphi method of achieving consensus. Proposed consensus statements were drafted by the Scientific Organising Committee and Session Chairs. Panel participants reviewed preliminary statements prior to the meeting and provided initial agreement and comments on the statement via online survey. During the meeting, discussion and debate occurred for each statement, after which a final vote was then held. Eighty per cent agreement was defined a priori as consensus. A total of 11 of 13 statements on operative versus non-operative treatment of ACL injury reached consensus during the Symposium. Nine statements achieved unanimous support, two reached strong consensus, one did not achieve consensus, and one was removed due to redundancy in the information provided. In highly active patients engaged in jumping, cutting and pivoting sports, early anatomical ACL reconstruction is recommended due to the high risk of secondary meniscus and cartilage injuries with delayed surgery, although a period of progressive rehabilitation to resolve impairments and improve neuromuscular function is recommended. For patients who seek to return to straight plane activities, non-operative treatment with structured, progressive rehabilitation is an acceptable treatment option. However, with persistent functional instability, or when episodes of giving way occur, anatomical ACL reconstruction is indicated. The consensus statements derived from international leaders in the field may assist clinicians in deciding between operative and non-operative treatment with patients after an ACL injur y . Level of evidence: Level V
Integrative molecular profiling of autoreactive CD4 T cells in autoimmune hepatitis
Authors: Amédée Renand, Iñaki Cervera-Marzal, Laurine Gil, Chuang Dong, Alexandra Garcia, Erwan Kervagoret, Hélène Aublé, Sarah Habes, Caroline Chevalier, Fabienne Vavasseur, Béatrice Clémenceau, Anaïs Cardon, Jean-Paul Judor, Jean-François Mosnier, Florence Tanné, David-Axel Laplaud, Sophie Brouard, Jérôme Gournay, Pierre Milpied, Sophie Conchon
Journal: Journal of Hepatology (2020)
Hyperglycemia But Not Hyperinsulinemia Is Favorable for Exercise in Type 1 Diabetes: A Pilot Study
Authors: Davide Romeres, Karen Olson, Rickey Carter, Claudio Cobelli, Chiara Dalla Man, Ananda Basu, Rita Basu
Journal: Diabetes Care (2020)

OBJECTIVE To distinguish the effects of hyperglycemia and hyperinsulinemia on exercise-induced increases in Rd and endogenous glucose production (EGP) in type 1 diabetes. RESEARCH DESIGN AND METHODS We studied six participants without diabetes and six participants with type 1 diabetes on three visits in random order for the following: euglycemia, low insulin (EuLoI); euglycemia, high insulin (EuHiI); and hyperglycemia, low insulin (HyLoI). Glucose fluxes were measured using [6,6-2H2] glucose before, during, and after 60 min of exercise. RESULTS Rd increased (P &amp;lt; 0.01) with exercise within groups, while peak Rd during exercise was lower (P &amp;lt; 0.01) in participants with type 1 diabetes than participants without diabetes during all visits. In type 1 diabetes participants, EGP increased (P &amp;lt; 0.001) with exercise during EuLoI and HyLoI but not during EuHiI. This demonstrates that hyperinsulinemia, but not hyperglycemia, blunts the compensatory exercise-induced increase in EGP in type 1 diabetes. CONCLUSIONS The data from this pilot study indicate that 1) exercise-induced compensatory increase in EGP was inhibited in participants with type 1 diabetes with hyperinsulinemia but not with hyperglycemia; 2) in contrast, in participants without diabetes, exercise-induced increase in EGP was inhibited only during combined hyperinsulinemia and hyperglycemia. Taken together, these results suggest that low insulin coupled with euglycemia or modest hyperglycemia appear to be the most favorable milieu for type 1 diabetes during exercise.
P-152 The impact of 2nd-line treatment after 1st-line gemcitabine plus nab-paclitaxel in advanced pancreatic cancer patients
Authors: M. Bensi, B. Di Stefano, M. Chiaravalli, M. Ribelli, A. Spring, M. Maratta, C. Bagalà, G. Tortora, L. Salvatore
Journal: Annals of Oncology (2020)
Antibodies Against Three Novel Peptides in Early Axial Spondyloarthritis Patients From Two Independent Cohorts
Authors: Dana Quaden, Patrick Vandormael, Pieter Ruytinx, Piet Geusens, Kristoff Corten, Johan Vanhoof, Jori Liesenborgs, Frank van Reeth, Anouk Agten, Frank Vandenabeele, Kurt de Vlam, Veerle Somers
Journal: Arthritis & Rheumatology (2020)

This study was undertaken to identify novel autoantibodies in axial spondyloarthritis (SpA) and determine their diagnostic potential in patients with early axial SpA and controls from 2 independent cohorts.An axial SpA complementary DNA phage display library was used to screen for novel IgG antibodies in plasma from patients with early axial SpA. The presence of these antibodies against novel peptides (i.e., peptides identified in an early axial SpA cohort from Hasselt University, designated UH-axSpA) was determined by enzyme-linked immunosorbent assay in 76 patients with early axial SpA, 75 controls with nonspecific chronic low back pain, 60 patients with rheumatoid arthritis, and 94 healthy controls from the UH cohort. Antibody reactivity to these novel peptides was further validated in 174 patients with axial SpA (of whom 79 had early axial SpA) from the University Hospitals Leuven (Bio)SPAR (Spondyloarthritis [Biologics]) cohort.We identified antibodies to 9 novel UH-axSpA peptides, corresponding to randomly formed peptides and to a novel axial SpA autoantigen, double homeobox protein 4. Antibodies to 3 UH-axSpA peptides with the highest positive likelihood ratio (LR) for a diagnosis of axial SpA were present in significantly more patients with early axial SpA from the UH and (Bio)SPAR cohorts (14.2% [22/155]) compared to controls with chronic low back pain (5% [4/75]), resulting in 95% specificity. The positive LR for confirming axial SpA using antibodies to these 3 UH-axSpA peptides was 2.7, which is higher than the LR obtained with the currently used laboratory marker C-reactive protein. Testing for antibodies to these 3 UH-axSpA peptides in patients with chronic low back pain increased the posttest probability of a diagnosis of axial SpA from 79% to 91%.Antibodies to 3 UH-axSpA peptides could provide a novel tool in the diagnosis of a subset of axial SpA patients.
P-361 High expression levels of circulating miRNA-618 and miRNA-203a-3p are associated with prolonged survival in patients with metastatic colon cancer
Authors: M. Radanova, D. Ivanova, G. Mihaylova, O. Tasinov, N. Nazifova-Tasinova, R. Manev, P. Pavlov, V. Petrova, D. Petkova, M. Mirchev, K. Bratoeva, N. Conev, Z. Mihaylova, I. Donev
Journal: Annals of Oncology (2020)
P-37 phase II study of oxaliplatin-based regimen in relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: INSPIRE study
Authors: M. Kotaka, K. Ishibashi, H. Satake, Y. Tsuji, M. Kataoka, M. Nakamura, N. Nagata, J. Sakamoto, K. Oba, H. Mishima
Journal: Annals of Oncology (2020)
Plasma Apolipoprotein E Levels and Risk of Dementia—You Are the Company You Keep
Authors: Madhav Thambisetty
Journal: JAMA Network Open (2020)

Manja Koch, PhD; Steven T. DeKosky, MD; Matthew Goodman, PhD; Jiehuan Sun, PhD; Jeremy D. Furtado, ScD; Annette L. Fitzpatrick, PhD; Rachel H. Mackey, PhD; Tianxi Cai, PhD; Oscar L. Lopez, MD; Lewis H. Kuller, MD; Kenneth J. Mukamal, MD; Majken K. Jensen, PhD
P-216 Incidence and trends of biliary tract cancer in Girona: A population-based study from the Girona Cancer Registry (1994-2016)
Authors: A. García Velasco, M. Quintana, M. Puigdemont Guinart, W. Carbajal, R. Guardeño Sanchez, V. Anna, A. Nica, A. Villavicencio, L. Vilardell, R. Marcos-Gragera
Journal: Annals of Oncology (2020)
Computation Through Neural Population Dynamics
Authors: Saurabh Vyas, Matthew D. Golub, David Sussillo, Krishna V. Shenoy
Journal: Annual Review of Neuroscience (2020)

Significant experimental, computational, and theoretical work has identified rich structure within the coordinated activity of interconnected neural populations. An emerging challenge now is to uncover the nature of the associated computations, how they are implemented, and what role they play in driving behavior. We term this computation through neural population dynamics. If successful, this framework will reveal general motifs of neural population activity and quantitatively describe how neural population dynamics implement computations necessary for driving goal-directed behavior. Here, we start with a mathematical primer on dynamical systems theory and analytical tools necessary to apply this perspective to experimental data. Next, we highlight some recent discoveries resulting from successful application of dynamical systems. We focus on studies spanning motor control, timing, decision-making, and working memory. Finally, we briefly discuss promising recent lines of investigation and future directions for the computation through neural population dynamics framework.